Betahistine STADA
Betahistine dihydrochloride — Oral tablet for Meniere's disease
Betahistine STADA contains betahistine dihydrochloride, a histamine analogue used to treat Meniere's disease — a chronic condition of the inner ear characterised by recurrent episodes of vertigo, tinnitus, and progressive hearing loss. Betahistine works by improving blood circulation in the inner ear and reducing endolymphatic pressure, helping to alleviate symptoms and reduce the frequency of vertigo attacks.
Quick Facts
Key Takeaways
- Betahistine STADA is a prescription medicine used to treat Meniere's disease, which causes vertigo, tinnitus, and hearing loss.
- The recommended starting dose is 16 mg three times daily (48 mg/day), which may be reduced to 8 mg three times daily based on response.
- Common side effects include nausea, indigestion, and headache — taking it with food helps reduce stomach problems.
- It should not be used in patients with pheochromocytoma, and caution is required for those with peptic ulcers, asthma, or low blood pressure.
- Betahistine may take several weeks to reach full effectiveness — do not stop treatment without consulting your doctor.
What Is Betahistine STADA and What Is It Used For?
Betahistine STADA belongs to a class of medications known as histamine analogues. The active substance, betahistine dihydrochloride, acts on histamine receptors in the body, particularly those involved in the regulation of blood flow to the inner ear. By modulating these receptors, betahistine helps restore normal vestibular function and reduces the frequency and severity of vertigo attacks associated with Meniere's disease.
Meniere's disease is a chronic condition of the inner ear that affects approximately 50 to 200 per 100,000 people worldwide, according to epidemiological data published by the WHO. The condition is characterised by a triad of symptoms: episodic vertigo (a sensation of spinning), fluctuating sensorineural hearing loss, and tinnitus. Many patients also experience a sensation of fullness or pressure in the affected ear. These symptoms can be profoundly disabling, significantly impacting quality of life, work productivity, and psychological wellbeing.
The precise mechanism by which betahistine exerts its therapeutic effects involves two complementary actions. First, it acts as a partial agonist at histamine H1 receptors, which promotes vasodilation and increases blood flow through the microvasculature of the inner ear, particularly the stria vascularis of the cochlea. Second, it functions as a potent antagonist at histamine H3 receptors, which further enhances cochlear and vestibular blood flow and may also facilitate central vestibular compensation through effects on histamine neurotransmission in the brain.
Clinical studies, including those reviewed by the European Medicines Agency (EMA), have demonstrated that betahistine can reduce both the frequency and severity of vertigo episodes in patients with Meniere's disease. The drug has been widely used across Europe, Asia, and other regions for over 40 years and remains a mainstay of pharmacological management for this condition. A Cochrane systematic review (2016) noted the need for further high-quality trials but acknowledged the clinical experience supporting its use.
It is important to understand that betahistine treats the symptoms of Meniere's disease but does not cure the underlying condition. Long-term management typically involves a combination of pharmacological therapy, dietary modifications (particularly sodium restriction), and lifestyle adjustments. Your doctor will determine whether betahistine is appropriate for your specific clinical situation and may combine it with other therapeutic approaches as needed.
What Should You Know Before Taking Betahistine STADA?
Contraindications
There are specific medical situations in which Betahistine STADA must not be taken. Understanding these contraindications is essential for safe use of this medication.
- You are allergic (hypersensitive) to betahistine dihydrochloride or any of the other ingredients in this medicine (listed in the Ingredients section below).
- You have pheochromocytoma — a rare tumour of the adrenal glands that causes high blood pressure. Because betahistine is a histamine analogue, it could theoretically trigger catecholamine release from a pheochromocytoma, leading to a dangerous hypertensive crisis.
If either of these conditions applies to you, do not take this medicine and speak with your doctor immediately. Your healthcare provider can suggest alternative treatments for your symptoms.
Warnings and Precautions
Before starting treatment with Betahistine STADA, it is important to inform your doctor if you have any of the following conditions, as they may require special monitoring or dose adjustment:
- Peptic ulcer disease (active or history of stomach or duodenal ulcers) — Betahistine may stimulate gastric acid secretion through its action on H1 receptors, potentially exacerbating ulcer symptoms. Your doctor may need to prescribe concurrent gastroprotective therapy.
- Bronchial asthma — Because betahistine has H1 agonist activity, there is a theoretical risk of bronchospasm in susceptible individuals. Your doctor will assess the benefit-risk ratio and may wish to monitor your respiratory function during treatment.
- Urticaria, skin rashes, or allergic rhinitis — If you suffer from allergic conditions, betahistine's histamine-like activity could potentially worsen these symptoms. Careful observation is recommended during the initial phase of treatment.
- Hypotension (low blood pressure) — Betahistine's vasodilatory properties may cause a further reduction in blood pressure in patients who already have low baseline readings. Blood pressure should be monitored appropriately.
Your doctor will evaluate whether it is safe for you to begin treatment and will advise on appropriate monitoring. Regular follow-up appointments may be scheduled to assess treatment response and identify any adverse effects early.
Children and Adolescents
Betahistine STADA is not recommended for use in children and adolescents under 18 years of age. There is insufficient clinical data regarding safety and efficacy in this age group. Meniere's disease is exceptionally rare in paediatric populations, and management in younger patients should be directed by a specialist otolaryngologist or paediatric neurologist.
Pregnancy and Breastfeeding
If you are pregnant, planning to become pregnant, or breastfeeding, you should discuss the use of Betahistine STADA with your doctor before starting treatment.
- Pregnancy: Do not take Betahistine STADA during pregnancy unless your doctor has determined that the potential benefit justifies the potential risk to the foetus. Animal reproduction studies have not provided sufficient data, and there is limited clinical experience in pregnant women.
- Breastfeeding: It is not known whether betahistine or its metabolites are excreted in human breast milk. Do not breastfeed while taking Betahistine STADA unless specifically advised by your doctor. The decision should weigh the benefit of breastfeeding for the child against the therapeutic benefit for the mother.
- Fertility: There are no clinical studies specifically assessing the effect of betahistine on human fertility. Consult your doctor if you are planning to conceive.
Driving and Using Machines
Betahistine STADA is not expected to directly affect your ability to drive or operate machinery. However, it is important to recognise that Meniere's disease itself can cause episodes of dizziness and nausea, which may impair your ability to perform these activities safely. Furthermore, in rare cases, the medication itself may contribute to these symptoms.
You are responsible for assessing whether you are fit to drive or operate machinery. Consider how the medication affects you personally, and consult your doctor or pharmacist if you are uncertain about your ability to perform these tasks safely.
How Does Betahistine STADA Interact with Other Drugs?
Drug interactions occur when one medication affects the way another medication works in the body. While betahistine has a relatively limited interaction profile compared to many other drugs, certain combinations warrant attention. Always provide your doctor or pharmacist with a complete list of all medications you are currently taking, have recently taken, or may potentially take.
Clinically Significant Interactions
| Drug / Class | Interaction Type | Clinical Effect | Recommendation |
|---|---|---|---|
| Antihistamines (e.g., cetirizine, loratadine, diphenhydramine) | Pharmacodynamic (antagonism) | Antihistamines may theoretically reduce the therapeutic effect of betahistine by blocking the H1 receptors that betahistine partially activates | Discuss with your doctor; monitor treatment response closely |
| MAO inhibitors (e.g., phenelzine, tranylcypromine, selegiline, rasagiline) | Pharmacokinetic (metabolic inhibition) | MAOIs inhibit the metabolism of betahistine, potentially increasing its blood levels and pharmacological effects | Use with caution; dose adjustment may be necessary; medical supervision advised |
| H2 receptor antagonists (e.g., ranitidine, famotidine) | Theoretical pharmacodynamic | Minimal clinical interaction expected, as betahistine primarily targets H1 and H3 receptors | Generally safe to combine; inform your doctor |
Additional Considerations
Betahistine is primarily metabolised by the enzyme monoamine oxidase (MAO) in the liver, being converted to its two main metabolites: 2-pyridylacetic acid (2-PAA, the primary metabolite) and 2-(2-aminoethyl)pyridine. Drugs that significantly alter MAO activity may therefore affect betahistine pharmacokinetics.
While formal drug interaction studies are limited, the following general principles should be considered:
- Alcohol: Although no specific pharmacokinetic interaction is documented, alcohol may worsen dizziness and nausea associated with Meniere's disease. Moderate alcohol intake is generally advised during treatment.
- Antihypertensives: Given betahistine's mild vasodilatory properties, additive blood pressure-lowering effects may occur in patients taking antihypertensive medications. Monitor blood pressure if starting or adjusting betahistine therapy.
- Beta-blockers: Theoretical additive effects on the cardiovascular system. Clinical significance is uncertain, but monitoring is advisable.
- Proton pump inhibitors (e.g., omeprazole, lansoprazole): No clinically significant interaction expected. May be used concurrently if gastric protection is needed.
If you are unsure about potential interactions with any other medication you take, consult your doctor or pharmacist before starting Betahistine STADA.
What Is the Correct Dosage of Betahistine STADA?
Always take Betahistine STADA exactly as your doctor or pharmacist has told you. Do not change your dose without medical advice. The dosage depends on your individual response to treatment, and your doctor may adjust it based on how well your symptoms are controlled and whether you experience any side effects.
Adults
Standard Adult Dosing
- Starting dose: 16 mg taken three times daily (total daily dose: 48 mg)
- Maintenance dose: May be reduced to 8 mg three times daily (total daily dose: 24 mg) depending on response
- Maximum daily dose: 48 mg (do not exceed this amount)
| Tablet Strength | Morning | Midday | Evening | Total Daily Dose |
|---|---|---|---|---|
| 8 mg tablets (maintenance dose) | 1 tablet (8 mg) | 1 tablet (8 mg) | 1 tablet (8 mg) | 24 mg |
| 16 mg tablets (starting dose) | 1 tablet (16 mg) | 1 tablet (16 mg) | 1 tablet (16 mg) | 48 mg |
| 24 mg tablets (alternative) | 1 tablet (24 mg) | — | 1 tablet (24 mg) | 48 mg |
Children and Adolescents
Betahistine STADA is not recommended for use in children and adolescents under 18 years of age due to insufficient data on safety and efficacy in this population. There are no paediatric-specific dosing guidelines available. If a young person requires treatment for vestibular symptoms, they should be referred to a specialist for appropriate evaluation and management.
Elderly Patients
No specific dose adjustment is routinely recommended for elderly patients. However, as older adults may have reduced renal and hepatic function, and are more likely to be taking multiple medications, treatment should be initiated under careful medical supervision. The British National Formulary (BNF) recommends standard adult dosing for elderly patients with appropriate clinical monitoring.
How to Take Betahistine STADA
Following these administration guidelines will help ensure you get the maximum benefit from your medication:
- Swallow the tablets whole with a glass of water. Do not crush, chew, or break the tablets (unless they have a score line for splitting).
- Take with or after food to minimise the risk of stomach upset, which is the most common side effect of betahistine.
- Space your doses evenly throughout the day. For example, take one tablet in the morning, one at midday, and one in the evening.
- Try to take your tablets at the same time each day to maintain consistent drug levels in your body and to help you remember your doses.
- Continue treatment as directed by your doctor, even if you start to feel better. The medication may take several weeks to reach its full therapeutic effect.
Missed Dose
If you forget to take a dose of Betahistine STADA, wait until it is time for your next scheduled dose and take it as normal. Do not take a double dose to make up for the one you missed. Taking extra medication will not improve your symptoms faster and may increase the risk of side effects.
Overdose
If you or someone else takes too much Betahistine STADA, symptoms of overdose may include nausea, vomiting, drowsiness, and stomach pain. Seek immediate medical attention by contacting your local poison control centre or going to the nearest emergency department. Bring the medicine packaging with you so healthcare professionals can identify exactly what has been taken.
Treatment of overdose is supportive and symptomatic. There is no specific antidote for betahistine overdose. Gastric lavage may be considered in cases of significant ingestion if the patient presents within one hour of ingestion.
Stopping Treatment
Do not stop taking Betahistine STADA without first consulting your doctor. Even if you begin to feel better, your doctor may want you to continue treatment for an extended period to ensure that the full therapeutic benefit is achieved and maintained. Abrupt discontinuation does not typically cause withdrawal symptoms, but your doctor should make the decision about when to stop therapy based on your overall clinical assessment.
What Are the Side Effects of Betahistine STADA?
Like all medicines, Betahistine STADA can cause side effects, although not everybody gets them. Most side effects are mild to moderate in severity and tend to resolve on their own or can be managed by taking the medication with food. Understanding the possible side effects and knowing when to seek medical help is an important part of managing your treatment safely.
- Hives (urticaria) or itchy, inflamed skin
- Swelling of the face, lips, tongue, or throat (angioedema)
- A drop in blood pressure leading to faintness or collapse
- Difficulty breathing or wheezing
If you experience any of these symptoms, stop taking the medicine immediately and seek emergency medical help.
Side Effects by Frequency
Common
- Nausea (feeling sick)
- Indigestion (dyspepsia)
- Headache
Other Reported Effects
- Vomiting
- Stomach pain (abdominal discomfort)
- Bloating (abdominal distension)
- Flatulence (excess gas)
Rare / Very Rare
- Hypersensitivity reactions (allergic reactions including skin rash, pruritus)
- Angioedema (swelling of deeper skin layers)
- Anaphylactic reactions (severe systemic allergic reaction)
Managing Common Side Effects
The most frequently reported side effects of betahistine are gastrointestinal in nature and are generally mild. Here are practical approaches to managing them:
- Nausea and indigestion: Taking Betahistine STADA with or immediately after food is the most effective strategy for reducing these symptoms. Avoid taking the medication on an empty stomach.
- Headache: If you develop a headache, a standard dose of paracetamol (acetaminophen) is usually sufficient. If headaches persist, consult your doctor.
- Stomach pain and bloating: These effects tend to diminish over time as your body adjusts to the medication. Eating smaller, more frequent meals may help.
Reporting Side Effects
Reporting suspected side effects after a medicine has been authorised is important. It allows ongoing monitoring of the benefit-risk balance of the medication. You can report side effects to your national medicines regulatory authority, such as the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom through the Yellow Card scheme, the European Medicines Agency (EMA) in the European Union, or the Food and Drug Administration (FDA) MedWatch programme in the United States. You can also report side effects directly to your doctor or pharmacist.
How Should You Store Betahistine STADA?
Proper storage of your medication ensures that it remains safe and effective throughout its shelf life. Follow these guidelines to maintain the quality of your Betahistine STADA tablets:
- Keep out of sight and reach of children — Store the medicine in a secure location where children cannot access it.
- Check the expiry date — Do not use Betahistine STADA after the expiry date (EXP) printed on the blister pack and carton. The expiry date refers to the last day of the indicated month.
- No special storage requirements — This medicine does not require any special temperature or humidity conditions. Store at normal room temperature.
- Keep in original packaging — Store the tablets in their original blister packaging to protect them from moisture and light.
Do not dispose of medicines by flushing them down the toilet or throwing them in household waste. Return any unused or expired medicines to your local pharmacy for safe disposal. This helps protect the environment and prevents accidental ingestion by others.
What Does Betahistine STADA Contain?
Active Ingredient
The active substance in Betahistine STADA is betahistine dihydrochloride. Each tablet is available in three strengths:
- 8 mg tablets: White to off-white, round (diameter 7.0 mm), flat, uncoated tablets embossed with "X" on one side and "87" on the other.
- 16 mg tablets: White to off-white, round (diameter 8.5 mm), uncoated tablets with "X" and a score line on one side and "88" on the other. These tablets can be split into two equal halves.
- 24 mg tablets: White to off-white, round (diameter 10.0 mm), uncoated tablets with "X" and a score line on one side and "89" on the other. These tablets can be split into two equal halves.
Inactive Ingredients (Excipients)
In addition to the active substance, Betahistine STADA tablets contain the following excipients, which serve various functions in the manufacturing and stability of the tablet:
| Excipient | Function |
|---|---|
| Microcrystalline cellulose | Filler and binder — provides bulk and structural integrity |
| Mannitol | Filler — provides tablet volume and improves taste |
| Povidone | Binder — helps hold the tablet ingredients together |
| Crospovidone | Disintegrant — helps the tablet break apart in the stomach |
| Citric acid | Acidifying agent — assists with tablet stability |
| Colloidal anhydrous silica | Glidant — improves powder flow during manufacturing |
| Talc | Lubricant and anti-adherent — prevents sticking during production |
| Stearic acid | Lubricant — facilitates tablet ejection from manufacturing dies |
Packaging
Betahistine STADA tablets (8 mg, 16 mg, and 24 mg) are supplied in polyamide/aluminium/PVC/aluminium blister packs. Available pack sizes include 20, 30, 50, 60, and 100 tablets, although not all pack sizes may be marketed in every country.
Frequently Asked Questions About Betahistine STADA
Betahistine STADA is used to treat Meniere's disease, a chronic condition of the inner ear. Meniere's disease causes recurrent episodes of vertigo (a spinning sensation), tinnitus (ringing or buzzing in the ears), and progressive hearing loss. Betahistine works by improving blood circulation in the inner ear and reducing the excess fluid pressure (endolymphatic hydrops) that is believed to underlie the symptoms of Meniere's disease. It helps reduce both the frequency and severity of vertigo attacks and may help stabilise hearing over time.
Betahistine may take several weeks to several months to show its full therapeutic effect. Some patients notice an improvement in vertigo episodes within the first two to four weeks of treatment, while others may need up to three months of consistent use before experiencing significant symptom relief. It is crucial to continue taking the medication as prescribed by your doctor, even if you do not notice immediate results. Your doctor will schedule regular follow-up appointments to assess your progress and determine whether the dose needs to be adjusted.
Betahistine can interact with certain medications. The most clinically relevant interactions are with antihistamines (such as cetirizine, loratadine, or diphenhydramine), which may theoretically reduce the effectiveness of betahistine, and with monoamine oxidase inhibitors (MAOIs), which can increase betahistine levels in the blood. Always inform your doctor or pharmacist about all the medicines you are taking, including over-the-counter medications, vitamins, and herbal supplements. In most cases, betahistine can be safely combined with other common medications under medical supervision.
The most commonly reported side effects of betahistine are nausea, indigestion (dyspepsia), and headache. These are classified as "common" side effects, meaning they may affect up to 1 in 10 people. Mild gastrointestinal symptoms such as vomiting, stomach pain, bloating, and gas have also been reported. Most of these side effects can be reduced or prevented by taking the medication with food. Serious allergic reactions are rare but can occur; if you notice hives, swelling of the face or throat, or difficulty breathing, seek immediate medical attention.
Betahistine should not be taken during pregnancy unless your doctor specifically determines that the benefit outweighs the potential risk. There is limited clinical data on the safety of betahistine in pregnant women, and animal studies have not been sufficient to rule out potential risks to the developing foetus. Similarly, it is not known whether betahistine passes into breast milk, so breastfeeding while taking this medicine is not recommended unless your doctor advises otherwise. If you discover that you are pregnant while taking betahistine, inform your doctor immediately so they can reassess your treatment plan.
The recommended starting dose for adults is 16 mg taken three times daily, giving a total daily dose of 48 mg. Depending on your response to treatment, your doctor may reduce the dose to 8 mg three times daily (24 mg total daily). The maximum daily dose should not exceed 48 mg. Tablets should be taken with food and swallowed whole with water. Betahistine is not recommended for children under 18 years of age. Always follow your doctor's dosing instructions precisely, and do not alter your dose without medical advice.
References
- James AL, Burton MJ. Betahistine for Meniere's disease or syndrome. Cochrane Database of Systematic Reviews. 2001;(1):CD001873. Updated 2016. doi:10.1002/14651858.CD001873.pub2
- European Medicines Agency (EMA). Betahistine — Summary of Product Characteristics. www.ema.europa.eu
- British National Formulary (BNF). Betahistine dihydrochloride. National Institute for Health and Care Excellence (NICE). bnf.nice.org.uk
- World Health Organization (WHO). WHO Model List of Essential Medicines, 23rd List. Geneva: World Health Organization; 2023. www.who.int/publications
- Murdin L, Hussain K, Schilder AG. Betahistine for symptoms of vertigo. Cochrane Database of Systematic Reviews. 2016;(6):CD010696. doi:10.1002/14651858.CD010696.pub2
- Adrion C, Fischer CS, Wagner J, et al. Efficacy and safety of betahistine treatment in patients with Meniere's disease: primary results of a long term, multicentre, double blind, randomised, placebo controlled, dose defining trial (BEMED trial). BMJ. 2016;352:h6816. doi:10.1136/bmj.h6816
- Lacour M, van de Heyning PH, Novotny M,"; Betahistine in the treatment of Meniere's disease. Neuropsychiatric Disease and Treatment. 2007;3(4):429-440.
- American Academy of Otolaryngology — Head and Neck Surgery. Clinical Practice Guideline: Meniere's Disease. Otolaryngology — Head and Neck Surgery. 2020;162(2_suppl):S1-S55.
- National Institute for Health and Care Excellence (NICE). Meniere's disease: management in primary and secondary care. www.nice.org.uk
- Strupp M, Hupert D, Frenzel C, et al. Long-term prophylactic treatment of attacks of vertigo in Meniere's disease — comparison of a high with a low dosage of betahistine. Acta Otolaryngologica. 2008;128(5):520-524.
Medical Editorial Team
This article was written and reviewed by our team of medical professionals who specialise in clinical pharmacology and otolaryngology. All content follows international medical guidelines and the GRADE evidence framework.
Licensed physicians with expertise in clinical pharmacology and ENT medicine. All authors have documented academic background and clinical experience in the management of vestibular disorders.
Independent panel of medical specialists who review all content according to EMA, WHO, and BNF guidelines before publication.
Last medically reviewed: | Evidence level: 1A (systematic reviews and RCTs) | Funding: No commercial funding